{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:51:56Z","timestamp":1790970716705,"version":"4.1.0"},"reference-count":28,"publisher":"SAGE Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1177\/1051228405001468","type":"journal-article","created":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T18:14:21Z","timestamp":1288116861000},"page":"16-23","source":"Crossref","is-referenced-by-count":36,"title":["SPECT Follow-Up Study of Cerebral Blood Flow Changes During Donepezil Therapy in Patients with Alzheimer's Disease"],"prefix":"10.1177","volume":"16","author":[{"given":"Soichiro","family":"Shimizu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruo","family":"Hanyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimihiko","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2006,2,16]]},"reference":[{"key":"10.1177\/1051228405001468-BIB1|cit2","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer's disease","volume":"2","author":"Davies","year":"1976","journal-title":"Lancet"},{"key":"10.1177\/1051228405001468-BIB2|cit3","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"10.1177\/1051228405001468-BIB3|cit4","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02245293","article-title":"Effects of a single dose of the acetylcholinesterase inhibitor velnacrine on recognition memory and regional cerebral blood flow in Alzheimer's disease","volume":"108","author":"Ebmeier","year":"1992","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1177\/1051228405001468-BIB4|cit5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00019442-200303000-00007","article-title":"Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study","volume":"11","author":"Tune","year":"2003","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1177\/1051228405001468-BIB5|cit6","first-page":"1441","article-title":"Donepezil hydrochloride preserves regional cerebral blood flow in patients with Alzheimer's disease","volume":"42","author":"Nakano","year":"2001","journal-title":"J Nucl Med"},{"key":"10.1177\/1051228405001468-BIB6|cit7","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S1388-2457(02)00110-4","article-title":"Effects of long-term Donepezil therapy on rCBF of Alzheimer's patients","volume":"113","author":"Nobili","year":"2002","journal-title":"Clin Neurophysiol"},{"key":"10.1177\/1051228405001468-BIB7|cit8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000068785","article-title":"Regional cerebral blood flow patterns and response to donepezil treatment in patients with Alzheimer's disease","volume":"15","author":"Hanyu","year":"2003","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1177\/1051228405001468-BIB8|cit9","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1097\/00001756-199705260-00011","article-title":"Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease","volume":"8","author":"Riekkinen","year":"1997","journal-title":"Neuroreport"},{"key":"10.1177\/1051228405001468-BIB9|cit10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00001756-200201210-00020","article-title":"Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease","volume":"13","author":"Vennerica","year":"2002","journal-title":"Neuroreport"},{"key":"10.1177\/1051228405001468-BIB10|cit11","first-page":"983","article-title":"Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors","volume":"43","author":"Nobili","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1177\/1051228405001468-BIB11|cit12","first-page":"1238","article-title":"A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET","volume":"36","author":"Minoshima","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1177\/1051228405001468-BIB12|cit13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1177\/1051228405001468-BIB13|cit14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.1177\/1051228405001468-BIB14|cit15","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1192\/bjp.140.6.566","article-title":"A new clinical scale for the staging of dementia","volume":"140","author":"Hughes","year":"1982","journal-title":"Br J Psychiatry"},{"key":"10.1177\/1051228405001468-BIB15|cit16","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1159\/000017259","article-title":"Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group","volume":"11","author":"Homma","year":"2000","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1177\/1051228405001468-BIB16|cit17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000051272","article-title":"Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease","volume":"12","author":"Doody","year":"2001","journal-title":"Dement Geriatr Cogn Disord"},{"key":"10.1177\/1051228405001468-BIB17|cit18","volume-title":"Co-planar Stereotactic Atlas of the Human Brain","author":"Talairach","year":"1998"},{"key":"10.1177\/1051228405001468-BIB18|cit19","first-page":"1528","article-title":"Anatomic standardization: Linear scaling and nonlinear warping of functional brain images","volume":"35","author":"Minoshima","year":"1994","journal-title":"J Nucl Med"},{"key":"10.1177\/1051228405001468-BIB19|cit20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/BF02988523","article-title":"Development of quantitative analysis method for stereotactic brain image: assessment of reduced accumulation in extent and severity using anatomical segmentation","volume":"17","author":"Mizumura","year":"2003","journal-title":"Ann Nucl Med"},{"key":"10.1177\/1051228405001468-BIB20|cit21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1192\/bjp.158.3.351","article-title":"Cerebral pharmacodynamics of physostigmine in Alzheimer's disease investigated using single-photon computerised tomography","volume":"158","author":"Hunter","year":"1991","journal-title":"Br J Psychiatry"},{"key":"10.1177\/1051228405001468-BIB21|cit22","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1523\/JNEUROSCI.14-04-02313.1994","article-title":"AMPA-induced excitotoxic lesions of the basal forebrain: a significant role for the cortical cholinergic system in attentional function","volume":"14","author":"Muir","year":"1994","journal-title":"J Neurosci"},{"key":"10.1177\/1051228405001468-BIB22|cit23","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1523\/JNEUROSCI.14-01-00167.1994","article-title":"Basal forebrain lesions in monkeys disrupt attention but not learning and memory","volume":"14","author":"Voytko","year":"1994","journal-title":"J Neurosci"},{"key":"10.1177\/1051228405001468-BIB23|cit24","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000118998","article-title":"Cholinergic control of cognitive resources","volume":"28","author":"Warburton","year":"1993","journal-title":"Neuropsychobiology"},{"key":"10.1177\/1051228405001468-BIB24|cit25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/BF02245253","article-title":"Reversal of visual attentional dysfunction following lesions of the cholinergic basal forebrain by physostigmine and nicotine but not by the 5-HT3 receptor antagonist, ondansetron","volume":"118","author":"Muir","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1177\/1051228405001468-BIB25|cit26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ddr.430310206","article-title":"Nicotinic potentiation of glutaminergic synapsesin the prefrontal cortex: New insight into the analysis of the role of nicotinicreceptors in cognitive functions","volume":"31","author":"Vidal","year":"1994","journal-title":"Drug Dev Res"},{"key":"10.1177\/1051228405001468-BIB26|cit27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/BF02244644","article-title":"Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB","volume":"110","author":"Sahakian","year":"1993","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1177\/1051228405001468-BIB27|cit28","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0924-977X(00)00067-5","article-title":"Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study","volume":"10","author":"Rogers","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1177\/1051228405001468-BIB28|cit29","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0140-6736(05)62221-0","article-title":"Guidelines on drug treatments for Alzheimer's disease","volume":"350","author":"Lovestone","year":"1997","journal-title":"Lancet"}],"container-title":["Journal of Neuroimaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1051228405001468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T08:11:53Z","timestamp":1626855113000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1177\/1051228405001468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"URL":"https:\/\/doi.org\/10.1177\/1051228405001468","relation":{},"ISSN":["1051-2284"],"issn-type":[{"value":"1051-2284","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}